When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?

Manuela Beda, Umberto Basso, Cristina Ghiotto, Silvio Monfardini

Research output: Contribution to journalArticlepeer-review

Abstract

We report the case of a woman with HER2-positive metastatic breast cancer who achieved prolonged complete remission of multiple liver metastases after treatment with weekly trastuzumab plus paclitaxel but relapsed in the brain soon after stopping trastuzumab maintenance therapy which had been prosecuted for almost three years. In the absence of randomized trials, the optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains questionable.

Original languageEnglish
Pages (from-to)491-492
Number of pages2
JournalTumori
Volume93
Issue number5
Publication statusPublished - Sep 2007

Keywords

  • Brain metastasis
  • Breast cancer
  • Duration of treatment
  • HER2
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research

Fingerprint

Dive into the research topics of 'When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?'. Together they form a unique fingerprint.

Cite this